Search academic texts

Information × Registration Number 0224U000141, 0121U112052 , R & D reports Title Development of the individual approaches to antiblastomic therapy in patients recovered from COVID-19. popup.stage_title Head Krasnoselskyi Mykola V., Доктор медичних наукStarenkyi Viktor P., Доктор медичних наук Registration Date 03-01-2024 Organization State Organization "Grigoriev Institute for Medical Radiologiy and Oncology of the National Academy of Medical Sciences of Ukraine" popup.description2  Object of study: oncology patients who have experienced COVID-19. Object of study: determine the indications and optimal conditions for carrying out antiblastoma therapy in patients who have suffered from COVID-19, by individualizing the terms, treatment regimens and accompanying therapy, taking into account clinical and laboratory characteristics. Methods and apparatus: clinical-instrumental, immunological, hematological, morphological, Respons 910 biochemical photoelectric automatic analyzer, SUNRISE TECAN microplate photometer, Spirocom spirographic complex, CHISON 17 diagnostic ultrasonic device, XN-L550 automatic hematological analyzer. Theoretical and practical results: the theoretical result is the justification of a panel of clinical and immunological markers. A decrease in the number of eosinophils and monocytes in combination with changes in the subpopulation of lymphocytes (the number of CD3+HLA, CD4+, CD8+ and NK-cells) has been proven, which indicates suppression and exhaustion of the antitumor response. The practical result is conducting a survey of patients, developing criteria for choosing the date of initiation of antiblastoma therapy based on a score on the comorbidity scale, taking into account anamnesis, concomitant pathology, clinical and immunological data. Novelty: for the first time, a comorbidity scale was developed for cancer patients taking into account the risk of severe complications of COVID-19. As the criteria for the start of antiblastoma therapy and the appointment of appropriate accompanying therapy, the value of points was chosen, where below 5 points there is no need to change the terms of treatment and additional symptomatic therapy, 6-10 points are the need for additional accompanying therapy, more than 10 points are a contraindication to carrying out antiblastoma therapy. The effectiveness of implementation: no. Field of use: oncology, medical radiology. Product Description popup.authors Artamonova Neonila Olehivna Artiukh Serhii Volodymyrovych Bilyi Oleksandr Mykolaiovych Bilozor Nataliia Volodymyrivna Bobrova Vladyslava Maksymivna Vasyliev Leonid Leonidovych Havrylenko Mykyta Vadimovich Hladkykh Fedir Volodymyrovych Hradil Hryhorii Ivanovych Hromakova Inna Serhiivna Zakrutko Anna Oleksandrivna Kantsedal Olena Mykolaivnа Kolomatska Viktoriia Volodymyrivna Lysenko Viktoriia Mykolaivna Lukashkova Olha Petrivna Maistrenko Ihor Oleksandrovych Niemykina Nadiia Viktorivna Nasonova Alla Mykolaivna Pidlisnyi Ruslan Anatoliiovych Prokhorova Elvira Borysivna Pushkar Olena Serhiivna Pshyshevska Liudmyla Anatoliivna Simonova-Pushkar Larysa Ivanivna Samofalov Ihor Oleksandrovych Svynarenko Andrii Viktorovych Semenenko Kseniia Oleksandrivna Slobodianiuk Olha Volodymyrivna Sorochan Pavlo Pavlovych Spuzyak Roman Mykhajlovych Sukhina Olena Mykolayivna Teslenko Iryna Mykolaivna popup.nrat_date 2024-01-03 Close